[…] leading to study drug discontinuation were reported through 96 weeks of dosing,” Fulcrum noted. “Every FSHD patient faces relentless and accumulating muscle and functional loss. These long-term data further demonstrate […]
Losmapimod continues to show promise
Int’l Research Congress Planning Committee
[…] genetic features of facioscapulohumeral muscular dystrophy, both in childhood and adulthood.She is involved in the FSHD natural history studies at the Radboudumc (FOCUS and iFOCUS), and has started to study […]
Walk Roll Volunteer Resources
[…] SPARK Engagement, Connection, Community, and Action! You’ll find essential information such as updates from the FSHD Society, ready access to forms and documents, upcoming training opportunities, access to past trainings […]
Avidity Announces New Positive AOC 1001 Data
[…] tolerability with over 200 infusions totaling 46.2 patient-years of exposure.” What does this mean for FSHD? The company is developing a similar drug, AOC 1020, for FSH muscular dystrophy, which […]
An ounce of prevention…
[…] are the second most common cause of injury leading to death. For a person with FSHD, falling and breaking a bone may be the incident that leads to becoming reliant […]